Lannett Advances Its Insulin Glargine Biosimilar

IND Submission With FDA Announced For Proposed Lantus Rival Developed With HEC

 
• By David Wallace
  
Road 2022 2023 2024
Lannett’s insulin glargine has taken the next step on the road to approval • Source: Alamy

More from Biosimilars

More from Products